| MICONAZOLE NITRATE
Monistat-Derm, Monistat 3, Monistat 7, Femizol-M, M-Zole, Micatin, Tetterine, Fungoid, Lotrimin AF, Desenex
Classifications: antibiotic; azole antifungal; Therapeutic: antibiotic; azole antifungal
Pregnancy Category: B
100 mg, 200 mg vaginal suppositories; 2% cream; 2% ointment; 2% powder; 2% spray; 2% solution
Broad-spectrum agent with fungicidal activity. Mode of action appears to inhibit uptake of components essential for cell
reproduction and growth as well as cell wall structure, thus promoting cell death of fungi.
Effective against Candida albicans and other species of this genus. Inhibits growth of common dermatophytes, and the organism responsible for tinea versicolor (Malassezia furfur).
Vulvovaginal candidiasis, tinea pedis (athlete's foot), tinea cruris, tinea corporis, and tinea versicolor caused by dermatophytes.
Hypersensitivity to miconazole; azole antifungal agents; children <2 y.
Pregnancy (category B), lactation.
Route & Dosage
Adult: Topical Apply cream sparingly to affected areas twice a day, and once daily for tinea versicolor, for 2 wk (improvement expected
in 23 d, tinea pedis is treated for 1 mo to prevent recurrence) Intravaginal Insert suppository or vaginal cream q h.s. x 7 d (100 mg) or 3 d (200 mg)
- Apply cream sparingly to intertriginous areas (between skin folds) to avoid maceration of skin.
- Massage affected area gently until cream disappears.
- Store at 15°30° C (59°86° F) unless otherwise directed.
Adverse Effects (≥1%)Urogenital:
Vulvovaginal burning, itching, or irritation; maceration, allergic contact dermatitis.
may increase INR with warfarin;
may inactivate nonoxynol-9
Small amount absorbed from vagina. Metabolism:
Rapidly metabolized in liver. Elimination:
In urine and feces. Half-Life:
Assessment & Drug Effects
- Expect clinical improvement from topical application in 1 or 2 wk. If no improvement in 4 wk, diagnosis is reevaluated.
Treat tinea pedis infection for 1 mo to assure permanent recovery.
Patient & Family Education
- Complete full course of treatment to ensure recovery.
- Do not interrupt vaginal application during menstrual period.
- Avoid contact of drug with eyes.